Categories: Technology

Mandatory disclosure of holding and notice of trade in IDEX Biometrics 23 July 2025

 | Source: IDEX BIOMETRICS ASA

Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. IDEX discloses the following information on behalf of a major shareholder and primary insider.

Tranche 1 of the private placement amounted to 4,731,594 shares. As disclosed separately, Pinchcliffe AS, a company closely related to CEO and CFO Anders Storbråten, participated in the private placement and subscribed for 739,360 shares in Tranche 1.

In connection with the private placement, the manager of the private placement, IDEX Biometrics and Mr. Storbråten entered into a share lending agreement.

Mr. Storbråten has lent 4,731,594 shares, ISIN NO0013536078, in connection with the settlement of Tranche 1. The shares have been lent, not sold, and will be returned in due course. 

After the subscription by Pinchcliffe and the temporary lending of shares, Mr. Storbråten and close relations hold 6,503,476 or 12,48% shares of the total outstanding shares and votes in IDEX Biometrics after completion of Tranche 1.

Contact person
Anders Storbråten, CEO and CFO
Tel: +47 4163 8582
E-mail: ir@idexbiometrics.com

About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

For more information, visit www.idexbiometrics.com

About this notice
This notice was issued by Erling Svela, Vice president of finance, on 23 July 2025 at 11:50 CET on behalf of IDEX Biometrics ASA. The information about the lending shall be disclosed according to article 19 no. 3 of the EU Market Abuse Regulation (EU 596/2014). The information about shareholding shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA). The information is published in accordance with section 5‑12 of the Norwegian Securities Trading Act.

GlobeNews Wire

Recent Posts

Tower Semiconductor Receives Best Supplier Award from Wisol for Excellence in RF SOI Technology and Supply Chain Support

MIGDAL HAEMEK, Israel, — July 30, 2025 - Tower Semiconductor, a leading foundry of high-value…

4 hours ago

Nano Labs Invests in BNB Strategic Reserve Company CEA INDUSTRIES INC. to Further Strengthen BNB Reserve Strategy

July 30, 2025 06:00 ET  | Source: Nano Labs Ltd. HONG KONG, July 30, 2025…

4 hours ago

Radware Reports Second Quarter 2025 Financial Results

Second Quarter 2025 Financial Results and Highlights Revenue of $74.2 million, an increase of 10%…

4 hours ago

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by…

5 hours ago

KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy

RIYADH, Saudi Arabia, July 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research…

5 hours ago

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:  Dr. Falk Pharma GmbH and…

5 hours ago